Of the few preclinical IPOs, Metagenomi keeps details about IND plans close

There’s no word yet on when Metagenomi will enter the clinic.

In its first quarterly update as a public company, the California biotech said Wednesday that its cash runway is set to take it into 2027 and bankroll two INDs along the way, but it was mum on when the first study could begin.

That didn’t surprise analysts since Metagenomi went public last month in one of the most high-profile preclinical IPOs in recent memory. The company is attempting to find new enzymes and create gene-editing tools.

Metagenomi’s performance as a publicly traded company could help sway when other preclinical startups, including fellow gene editing ones, make their own Wall Street entries. The company priced at the low end of its proposed range, at $15 a share $MGX, and its stock was…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks